A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related Comorbidity
Clinical trial NCT06693843 · COMPLETED
Trial details
- NCT number
- NCT06693843
- Sponsor
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-28
- Primary completion
- 2025-10-24
- Enrollment
- 230
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.